Laura Andrea
Charola Ramos
Investigadora en el període 2018-2021
Publicacions (42) Publicaciones en què ha participat algun/a investigador/a
2023
-
COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire
Gastroenterologia y Hepatologia, Vol. 46, Núm. 4, pp. 255-260
-
Efficacy, Efficiency, and Acceptability of Telemedicine for Inflammatory Bowel Disease Patients' Follow-Up Care during the COVID-19 Pandemic
Digestive Diseases, Vol. 41, Núm. 4, pp. 574-580
-
Hematological Composite Scores in Patients with Inflammatory Bowel Disease
Journal of Clinical Medicine, Vol. 12, Núm. 23
-
Impact of Biologic Agents on the Immune Response Induced by the Additional Dose of SARS-CoV-2 Vaccine in Inflammatory Bowel Disease Patients
Inflammatory bowel diseases, Vol. 29, Núm. 7, pp. 1165-1169
-
Serum Levels of Lipoprotein Lipase Are Increased in Patients with Inflammatory Bowel Disease
International journal of molecular sciences, Vol. 24, Núm. 6
2022
-
Adherence to subcutaneous biologic treatment for inflammatory bowel disease
Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 335-341
-
Apolipoprotein C3 Is Downregulated in Patients With Inflammatory Bowel Disease
Clinical and translational gastroenterology, Vol. 13, Núm. 6, pp. e00500
-
Immigrant IBD Patients in Spain Are Younger, Have More Extraintestinal Manifestations and Use More Biologics Than Native Patients
Frontiers in Medicine, Vol. 9
-
Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study
Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736
-
Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry
Journal of Clinical Medicine, Vol. 11, Núm. 2
-
Predictive factors for inadequate bowel cleansing in colon capsule endoscopy
Gastroenterologia y Hepatologia, Vol. 45, Núm. 8, pp. 605-613
-
Psychosocial impact of the COVID-19 pandemic on patients with inflammatory bowel disease in Spain. A post lockdown reflection
Gastroenterologia y Hepatologia, Vol. 45, Núm. 9, pp. 668-676
-
Real-world use of mycophenolate mofetil in inflammatory bowel disease: Results from the ENEIDA registry
Digestive and Liver Disease, Vol. 54, Núm. 5, pp. 635-641
-
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Journal of Clinical Medicine, Vol. 11, Núm. 24
-
Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab
Journal of Clinical Medicine, Vol. 11, Núm. 15
-
Validation of screening criteria for spondyloarthritis in patients with inflammatory bowel disease in routine clinical practice
Digestive and Liver Disease, Vol. 54, Núm. 6, pp. 755-762
2021
-
An Enhanced High-Volume Preparation for Colonoscopy Is Not Better Than a Conventional Low-Volume One in Patients at Risk of Poor Bowel Cleansing: A Randomized Controlled Trial
Frontiers in Medicine, Vol. 8
-
Carotid plaque assessment reclassifies patients with inflammatory bowel disease into very-high cardiovascular risk
Journal of Clinical Medicine, Vol. 10, Núm. 8
-
Diet and microbiome in the beginning of the sequence of gut inflammation
World Journal of Clinical Cases, Vol. 9, Núm. 36, pp. 11122-11147
-
Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry
Journal of Crohn's and Colitis, Vol. 15, Núm. 11, pp. 1846-1851